TAI-1|cas:1334921-03-7|西域试剂

TAI-1,98.02%

产品编号：Bellancom-B0790| CAS NO：1334921-03-7| 分子式：C₂₄H₂₁N₃O₃S| 分子量：431.51

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-B0790	￥900.00	杭州北京（现货）
Bellancom-B0790	￥1500.00	杭州北京（现货）
Bellancom-B0790	￥3000.00	杭州北京（现货）
Bellancom-B0790	￥4200.00	杭州北京（现货）
Bellancom-B0790	￥6200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

TAI-1

产品介绍

TAI-1 是具有口服活性的、抗肿瘤活性的化合物，是高效的、first-in-class Hec1 抑制剂，在 K562 细胞中的 GI₅₀ 值为 13.48 nM。

生物活性

TAI-1, an orally active anticancer agent, is a highly potent first-in-class Hec1 inhibitor, with a GI₅₀ of 13.48 nM in K562 cells.

体外研究

TAI-1 disrupts Hec1-Nek2 protein interaction, leads to Nek2 degradation, induces significant chromosomal misalignment in metaphase, and induces apoptotic cell death.
TAI-1 induces cancer cell death through the induction of cleavage of apoptotic proteins Caspase 3 and PARP and degradation of anti-apoptotic proteins MCL-1 and suggests that TAI-1 leads to activation of the apoptotic pathways.
TAI-1 is effective in many cancer cells, such as Chronic myeloid leukemia, Cervical cancer, Breast, metastatic-pleural, invasive ductal carcinoma, Acute myeloid leukemia, Myelogenous leukemia, Colorectal carcinoma cells, with GI₅₀ less than 100 nM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

TAI-1 (20 mg/kg intravenously IV/ or 150 mg/kg per oral PO/BID) inhibits tumor growth in multiple cancer xenograft models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C.B-17 SCID mice (6-7 weeks, 21-24 g).
Dosage:	20 mg/kg intravenously IV/ or 150 mg/kg per oral PO/BID.
Administration:	QDx28 cycles.
Result:	Led to significant tumor growth retardation in Huh-7 and modest tumor inhibition was noted tor the Colo205 and MDA-MB-231 models. Did not lead to any loss in body weight.

体内研究

TAI-1 (20 mg/kg intravenously IV/ or 150 mg/kg per oral PO/BID) inhibits tumor growth in multiple cancer xenograft models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C.B-17 SCID mice (6-7 weeks, 21-24 g).
Dosage:	20 mg/kg intravenously IV/ or 150 mg/kg per oral PO/BID.
Administration:	QDx28 cycles.
Result:	Led to significant tumor growth retardation in Huh-7 and modest tumor inhibition was noted tor the Colo205 and MDA-MB-231 models. Did not lead to any loss in body weight.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (231.74 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3174 mL	11.5872 mL	23.1744 mL
5 mM	0.4635 mL	2.3174 mL	4.6349 mL
10 mM	0.2317 mL	1.1587 mL	2.3174 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.79 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.79 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。